U.S. flag

An official website of the United States government

Display Settings:

Items per page
You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 6

1.
Figure 6

Figure 6. From: Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.

Treatment-emergent categorical lipid changes.

Virginia L Stauffer, et al. BMC Psychiatry. 2010;10:89-89.

CitationFull text

2.
Figure 1

Figure 1. From: Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.

Patient disposition. Diagram summarizing patient disposition.

Virginia L Stauffer, et al. BMC Psychiatry. 2010;10:89-89.

CitationFull text

3.
Figure 5

Figure 5. From: Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.

Percentage of patients experiencing adverse categorical glucose changes at anytime.

Virginia L Stauffer, et al. BMC Psychiatry. 2010;10:89-89.

CitationFull text

4.
Figure 4

Figure 4. From: Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.

Estimated change in weight in olanzapine-treated black and white patients over 24 weeks. Graph based on MMRM Model including fixed terms baseline weight, treatment week, protocol, investigator, race, and ethnic origin × treatment week. Race P-value = 0.13.

Virginia L Stauffer, et al. BMC Psychiatry. 2010;10:89-89.

CitationFull text

5.
Figure 2

Figure 2. From: Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.

Estimated change in PANSS total score in olanzapine-treated black and white patients over 24 weeks. Graph based on MMRM Model including fixed terms baseline PANSS total score, treatment week, protocol, investigator, race, and ethnic origin × treatment week. Race P-value = 0.93.

Virginia L Stauffer, et al. BMC Psychiatry. 2010;10:89-89.

CitationFull text

6.
Figure 3

Figure 3. From: Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.

Estimated change in CGI-Severity score in olanzapine-treated black and white patients over 24 weeks. A statistically significant difference was found in the effect of race with respect to time (P = 0.027). Black patients showed a more rapid improvement in the first 5 weeks.

Virginia L Stauffer, et al. BMC Psychiatry. 2010;10:89-89.

CitationFull text

Display Settings:

Items per page

Supplemental Content

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center